Nealon et al.

1 Association between Fuchs Endothelial Corneal Dystrophy, Diabetes Mellitus and

2 Multimorbidity

- 3
- 4 Cari L. Nealon, OD,^{1,#} Christopher W. Halladay, MS,^{2,#} Bryan R. Gorman, OD,^{3,4,#} Piana
- 5 Simpson, OD,¹ David P. Roncone, OD,¹ Rachael L. Canania, OD,¹ Scott A. Anthony, OD,¹
- 6 Lea R. Sawicki Rogers, OD,⁵ Jenna N. Leber, OD, ⁵ Jacquelyn M. Dougherty, OD, ⁵ Jessica
- N. Cooke Bailey, PhD, PhD,^{6,7,8} Dana C. Crawford, PhD,^{6,7,8} Jack M. Sullivan, MD, PhD,^{5,9,10}
- 8 Anat Galor, MD, MSPH,^{11,12} Wen-Chih Wu, MD,¹³ Paul B. Greenberg, MD,^{14,15} the Million
- 9 Veteran Program, Jonathan H. Lass, MD,^{16,17} Sudha K. Iyengar, PhD,^{6,7,8,§} Neal S. Peachey,
- 10 PhD^{8,18,19,§}
- 11

12 Author affiliations:

- ¹ Eye Clinic, VA Northeast Ohio Healthcare System, Cleveland, Ohio, USA
- ² Center of Innovation in Long Term Services and Supports, Providence VA Medical Center,
- 15 Providence, Rhode Island, USA
- ¹⁶ ³ VA Cooperative Studies Program, VA Boston Healthcare System, Boston, Massachusetts
- ⁴ Booz Allen Hamilton, McLean, Virginia, USA
- ⁵ Ophthalmology Section, VA Western NY Health Care System, Buffalo, New York, USA
- ⁶ Cleveland Institute for Computational Biology, Case Western Reserve University School of
- 20 Medicine, Cleveland, Ohio, USA
- ⁷ Department of Population & Quantitative Health Sciences, Case Western Reserve
- 22 University School of Medicine, Cleveland, Ohio, USA
- ⁸ Research Service, VA Northeast Ohio Healthcare System, Cleveland, Ohio, USA
- ⁹ Research Service, VA Western NY Health Care System, Buffalo, New York, USA
- ¹⁰ Department of Ophthalmology (Ross Eye Institute), University at Buffalo-SUNY, Buffalo,
- 26 New York, USA
- 27 ¹¹ Miami Veterans Affairs Medical Center, Miami, Florida, USA
- ¹² Bascom Palmer Eye Institute, University of Miami, Miami, Florida, USA
- ¹³ Cardiology Section, Medical Service, Providence VA Medical Center, Providence, Rhode
 Island, USA
- ¹⁴ Ophthalmology Section, Providence VA Medical Center, Providence, Rhode Island, USA

- ¹⁵ Division of Ophthalmology, Alpert Medical School, Brown University, Providence, Rhode
- 33 Island, USA
- ¹⁶ Department of Ophthalmology & Visual Sciences, Case Western Reserve University,
- 35 Cleveland, Ohio, USA
- ¹⁷ University Hospitals Eye Institute, Cleveland, Ohio, USA
- ¹⁸ Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
- ¹⁹ Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine of Case
- 39 Western Reserve University, Cleveland, Ohio, USA
- 40 [#] These authors contributed equally to this work
- 41 § These authors jointly supervised this work
- 42
- 43 Correspondence:
- 44 Neal S. Peachey, Research Service (151W), VA Northeast Ohio Healthcare System, 10701
- 45 East Boulevard, Cleveland OH 44106, USA (<u>neal.peachey@va.gov</u>; 216-791-3800 x64661);
- 46 Sudha K. Iyengar, Case Western Reserve University School of Medicine, 2103 Cornell Road,
- 47 Cleveland, OH 44106, USA (<u>ski@case.edu</u>; 216-368-4388)
- 48
- 49 Conflict of interest: none
- 50

51 Key words: Corneal dystrophy, diabetes, comorbidity, Fuchs endothelial corneal dystrophy

52

Supported by the VA Office of Research & Development (I01 BX003364), the Cleveland 53 Institute for Computational Biology, NIH Core Grants (P30 EY025585, P30 EY011373), the 54 Clinical and Translational Science Collaborative of Cleveland (UL1TR002548) from the 55 National Center for Advancing Translational Sciences (NCATS) component of the NIH and 56 NIH Roadmap for Medical Research, and unrestricted grants from Research to Prevent 57 58 Blindness to Case Western Reserve University, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and the University of Buffalo. This work was also 59 supported by the Harper-Inglis Memorial for Eye Research, The Peierls Foundation, and That 60 Man May See. 61

62

63 **Abstract**

- Purpose: To assess risk for demographic variables and other health conditions that are
 associated with Fuchs endothelial corneal dystrophy (FECD).
- 66 **Methods:** We developed a FECD case-control algorithm based on structured EHR data and 67 accuracy confirmed by individual review of charts at three VA Medical Centers. This algorithm 68 was applied to the Department of Veterans Affairs Million Veteran Program cohort from whom 69 sex, genetic ancestry, comorbidities, diagnostic phecodes and laboratory values were
- extracted. Single and multiple variable logistic regression models were used to determine the
- association of these risk factors with FECD diagnosis.
- 72 **Results:** Being a FECD case was associated with female sex, European genetic ancestry,
- and a greater number of comorbidities. Of 1417 diagnostic phecodes evaluated, 213 had a
- significant association with FECD, falling in both ocular and non-ocular conditions, including
- diabetes mellitus (DM). Five of 69 laboratory values were associated with FECD, with the
- direction of change for four being consistent with DM. Insulin dependency and type 1 DM
- raised risk to a greater degree than type 2 DM, like other microvascular diabetic
- 78 complications.
- Conclusions: Female gender, European ancestry and multimorbidity increased FECD risk.
 Endocrine/metabolic clinic encounter codes as well as altered patterns of laboratory values
 support DM increasing FECD risk. Our results evoke a threshold model in which the FECD
 phenotype is intensified by DM and potentially other health conditions that alter corneal
 physiology. DM may modify FECD onset and encourage progression among susceptible
 individuals, suggesting that optimizing glucose control may be an effective preventative for
 FECD.
- 86
- 87 Running Head: Fuchs Endothelial Corneal Dystrophy

Longitudinal electronic health records (EHRs) represent an amazing opportunity to identify 88 previously unappreciated or unrecognized relationships between complex conditions. In the 89 present study, we focused on Fuchs endothelial corneal dystrophy (FECD) a common 90 corneal dystrophy and a leading indication for corneal transplantation in the United States 91 92 (US).¹⁻⁴ FECD is an important healthcare challenge with an estimated prevalence in the adult population of 4%.⁵ FECD is characterized by bilateral endothelial cell pleomorphism and 93 polymegathism, decreased endothelial cell density, guttae, and corneal edema.^{1,6} Two 94 subtypes are recognized based on the age of onset. The early subtype, linked to mutations in 95 the COL8A2 gene, is rare and considered to have a more severe disease course.^{7,8} The 96 97 more common late subtype has an onset during the second or third decade becoming symptomatic in the fifth to sixth decade⁶ with well-established links to mutations in *TCF4* and 98 SLC4A11.9 99

The etiology of FECD involves a complex interaction between incompletely penetrant 100 genetic factors that increase risk and biological and environmental factors that contribute to 101 disease manifestation.⁴ The profile of genetic risk related to FECD has become clearer 102 thanks to recent large-scale genetic analyses.¹⁰ Biological factors such as estrogen levels 103 and oxidative stress, and environmental factors such as UV light exposure, have been 104 implicated in FECD.^{4,11} This increased understanding of FECD pathogenesis prompted the 105 present study, wherein we reasoned that additional genetic, non-genetic biological and 106 107 environmental factors that relate to FECD might also be involved in other disorders, and thus lead to an increased incidence in patients with FECD. This possibility has not been a major 108 research focus but is supported from two reports. Xu and colleagues¹² analyzed a U.S. 109 Medicare database to demonstrate that patients with FECD were at increased risk for breast, 110 ovarian, thyroid and several cutaneous malignancies, while also being at decreased risk for 111 lung and prostate cancer. Chang and colleagues¹³ analyzed the Taiwan Longitudinal Health 112 Insurance Database 2000 and noted that patients with ocular allergic conditions were more 113 likely to be diagnosed with FECD. These reports motivate our effort to comprehensively 114 analyze the relationship between FECD and other disease phenotypes. To achieve this goal, 115 we used the US Department of Veterans Affairs (VA) sponsored Million Veteran Program 116 (MVP), an ongoing observational cohort and mega-biobank, to explore whether other disease 117 phenotypes are associated with FECD. MVP integrates data from EHRs, health surveys, and 118 genomic data,^{14,15} with more than 825,000 Veterans successfully enrolled across the VA 119

- 120 healthcare system (www.mvp.va.gov). MVP has substantial ethnic diversity that parallels the
- 121 US population providing research opportunities across multiple ethnic groups.¹⁵

Before embarking on this analysis, we first addressed an important challenge in using 122 EHR-linked biobanks to accurately identify cases and controls through computable or 123 electronic phenotyping. Computable phenotyping utilizes diagnostic, procedure, and office 124 visit codes as well as prescription and/or laboratory tests to identify cases and controls for the 125 disease of interest.¹⁶ Rules-based algorithms have been successfully used within MVP to 126 identify other ocular diseases including age-related macular degeneration¹⁷ and primary open 127 angle glaucoma.¹⁸ To support our analysis, we developed a FECD phenotype algorithm 128 based on International Classification of Diseases Clinical Modification (ICD-CM) codes and 129 Current Procedural Terminology (CPT) codes to accurately identify FECD cases and controls 130 within the VA Computerized Patient Record System (CPRS).¹⁹ 131

We used our FECD case-control algorithm to conduct a phenotype wide association 132 study (PheWAS) for FECD. Although PheWAS was originally developed to understand 133 genetic pleiotropy,²⁰ the use of PheWAS has been broadened to identify relationships 134 between a disease of interest and other conditions.^{21,22} Herein we used the PheWAS 135 approach to identify relationships between FECD and other disease phenotypes. Considering 136 prior reports that FECD incidence may be higher in females^{4,23,24} and may vary between 137 racial groups^{25,26} we incorporated these factors into our analysis and noted that female sex 138 and European ancestry were associated with FECD. Our main finding was that diagnostic 139 codes for multiple ocular and non-ocular conditions were elevated in FECD cases. Further, 140 these associations and laboratory value alterations identified in FECD indicate that diabetes 141 mellitus (DM) may contribute to the development of FECD. 142

143

144 Materials & Methods

145 **Study Participants**

146 The MVP provides access to health, genetic and lifestyle information for U.S. Veterans who

- 147 provided informed consent (https://www.research.va.gov/mvp/). When this study was
- conducted, MVP had provided data for 658,582 Veterans. Local chart reviews were
- 149 conducted at the Eye Clinics of three VA Medical Centers (VAMCs; VA Northeast Ohio
- 150 Healthcare System (Cleveland, OH), Providence VA Medical Center (Providence, RI), and
- 151 VA Western New York Healthcare System (Buffalo, NY). This study adhered to the tenets of

- the Declaration of Helsinki and was approved by the VA Office of Research & Development
- 153 Central Institutional Review Board (VA CIRB 18-41).
- 154

155 Developing a Case-Control Algorithm for FECD

156 We designed a rules-based algorithm utilizing structured EHR data (ICD-9-CM, ICD-10-CM, and CPT codes) to identify FECD cases and controls within CPRS at each VAMC. Cases 157 greater than 18 years old were identified based on the presence of two FECD ICD-9-CM or 158 ICD-10-CM codes along with the absence of other ICD-9-CM or ICD-10-CM codes for 159 corneal conditions or complicated cataract surgery that could confound the diagnosis. 160 161 Controls were identified by excluding ICD-9-CM or ICD-10-CM codes for FECD, confounding corneal conditions, and complicated cataract surgery in Veterans 65 years and older. The 162 algorithm was refined over five iterations; in each iteration, we used the algorithm to identify 163 up to 25 cases and 25 controls, in both non-Hispanic white (NHW) and non-Hispanic black 164 (NHB) Veterans and evaluated algorithm performance in those patients with chart reviews. 165 Race and ethnicity were based on the consensus self-reported identify maintained by the VA 166 167 Information Resource Center.

Chart review by Cleveland VAMC optometrists allowed for our FECD case-control 168 algorithm to be tested and refined until the final version was determined. To be confirmed as 169 a case, Veterans must have documented slit lamp findings of bilateral corneal endothelial 170 pathology. These structural signs were accompanied by FECD-relevant descriptors: bilateral 171 corneal guttae, a "beaten metal appearance", stromal corneal edema, bullae, and bullous 172 keratopathy.^{1,6} Case exclusion criteria included prior complicated ocular surgeries or traumas 173 causing secondary corneal endothelial disease. Cases of postoperative intraocular surgery 174 with pseudophakic corneal edema, pseudophakic bullous keratopathy, or corneal 175 decompensation were included if FECD was documented pre-operatively. Clinicians were 176 instructed to use best clinical judgment and available clinical documentation to determine 177 inclusion status. 178

To be confirmed as controls, Veterans must have no signs of FECD or any other
 corneal endothelial disease. Finalized inclusion criteria codes included H18.51 for ICD-10-CM
 and 371.57 for ICD-9-CM. Exclusion criteria codes are displayed in Supplementary Table 1.
 Figure 1 presents an overview of the process used to evaluate algorithm performance.
 We first calculated positive and negative predictive values (PPV, NPV) for the Cleveland

VAMC site, in parallel for NHB and NHW Veterans. Once we achieved >85% PPV and NPV
 at the Cleveland VAMC, the algorithm was also evaluated by Eye Clinic staff at the Buffalo
 and Providence VAMCs.

187

188 Analyses Within the Million Veteran Program Biobank

We applied the final FECD case-control algorithm to the available MVP cohort of 658,582
Veterans with available genetic data. Following identification of cases and controls, data on
sex and current age were extracted from medical records or the MVP baseline lifestyle
survey. Using participant genotypes²⁷ we classified individuals by genetic ancestry into
admixed African (AFR), Asian (ASN), European (EUR), and admixed American (HIS)
populations via the HARE (harmonized ancestry and race/ethnicity) machine learning
algorithm.²⁸

We used single and multiple variable logistic regression to understand the impact of 196 sex, genetic ancestry (coded as a categorical variable) and Charlson Comorbidity Index (CCI) 197 on FECD. Since our algorithm used age to select cases and controls, we could not test the 198 199 effect of age, but did use this variable to adjust for confounding. In our multiple regression model, we also examined comorbidity in cases and controls using the CCI.²⁹ Based on prior 200 reports that US adults have an average of 2.2 comorbid conditions,^{30,31} we compared 201 Veterans without comorbid conditions to those with either 1-3 or 4 or more comorbidities, 202 203 coded as categorical variables.

204

205 Association of FECD Diagnosis with other Phenotypes and Laboratory Values

Phecodes combine ICD codes into clinically meaningful phenotypes^{32,33} and have traditionally 206 been used to perform PheWAS in the context of genetic risk factors.²⁰ In our study we used 207 phecodes to understand phenotypic relationships between FECD and multiple conditions. We 208 also determined if relationships existed between FECD and laboratory values. Phenotype 209 and laboratory analyses were both implemented in the R PheWAS package.³⁴ For each ICD 210 code, cases were defined as at least 2 counts of the code on separate days, and controls 211 were 0 counts. Subjects with 1 count were excluded. Additionally, we applied phenotype-212 based control exclusion (i.e., exclusion of controls that were cases in similar phenotypes) and 213 214 we excluded females in male-specific phenotypes and vice versa. We only considered phenotypes with 100 or more cases. For laboratory values, we used the median value in 215

- regression analyses, and required that everyone had at least two lab measurements to be
- included. Labs with measurements in at least 50 individuals were considered. All ICD code-
- based phenotypes were tested with logistic regression, and all lab-based phenotypes were
- tested with linear regression, adjusting for age, age-squared, sex (for non-sex specific
- 220 phenotypes), and 20 Principal Components of genome-wide genetic markers representing
- 221 population structure in both.
- 222
- 223 Results

224 Developing an Accurate FECD Case-Control Algorithm

Initial algorithm development and refinement via chart review was completed at the Cleveland

VAMC Eye Clinic. At each iteration, the algorithm identified 50 putative cases (25 NHW, 25

NHB) and 50 putative controls (25 NHW, 25 NHB) whose charts were then individually

reviewed. The first four iterations identified errors which were used to refine the algorithm.

For example, during early algorithm development, multiple putative cases were identified as epithelial basement membrane dystrophy which affects the corneal epithelium rather than the endothelium which is involved in FECD. Control accuracy was also affected by coding errors. For example, some putative controls had clear changes to the corneal endothelium (guttae)

but this was not coded in the medical record.

For the fifth and final iteration, review of the cases identified six errors in which postoperative complications made it difficult to determine if FECD was present before surgical intervention, yielding a PPV of 88%. Review of the 50 controls identified three errors where guttae were present, but a FECD ICD-9-CM or ICD-10-CM was not recorded in the chart, yielding a NPV of 94%.

We next evaluated algorithm performance at the Buffalo VAMC and Providence VAMC
Eye Clinics. At Buffalo, 42 FECD cases (25 NHW, 17 NHB) and 50 controls (25 NHW, 25
NHB) were identified by the algorithm. After chart review by eye care providers, a PPV of
78% and NPV of 98% were determined. At Providence, 26 FECD cases (25 NHW, 1 NHB)
and 49 (24 NHW, 25 NHB) controls were reviewed by eye care providers. The PPV was 77%
while the NPV was 100%.

Combined across all three VA sites, the FECD algorithm performed with an 82% PPV and 97% NPV (**Table 1**). The PPV was higher in NHB Veterans (93%) than in NHW Veterans (76%). NPV was similar between NHB and NHW Veterans at 98% and 96%, respectively.

248

249 **FECD Risk Factors include Female Sex and European Ancestry**

When applied to the genotyped MVP cohort, the algorithm identified 2,663 cases and 250 146,659 controls (**Table 2**), exceeding the sizes of the case and control cohorts analyzed in 251 the largest reported genome-wide association study for FECD.¹⁰ While this seems like a 252 large drop-off from the original MVP cohort of 658,582, a major factor is the requirement that 253 controls be 65 years of age or older and presence of an eye exam. Most cases and controls 254 were male, reflecting the historical prevalence of males in the U.S. military and that >90% of 255 MVP enrollees are male.³⁵ Stratified by ancestry, our algorithm identified 2,264 EUR, 315 256 AFR, 80 HIS, and 4 ASN cases, partially reflecting the relative ancestry proportions in MVP 257 (~70% EUR overall). 258

Prior reports indicate the frequency of FECD is elevated in females as compared to 259 males, although the estimate of the magnitude of this difference varies^{4,23,24} and has not been 260 examined in diverse populations. We examined the frequency of females vs. males among 261 cases and noted that the frequency of FECD varied across race and was much higher in 262 263 females (Table 2). Single variable logistic regression (Supplementary Table 2) showed that FECD cases had a 5.6X greater odds of being female (OR=5.60; CI: 4.93-6.33; $p = 1.07 \times 10^{-1}$ 264 ¹⁶⁰). Single variable analysis of genetic ancestry as a categorical variable (EUR *vs* AFR, EUR 265 vs HIS, and EUR vs ASN) showed that individuals of EUR ancestry were at greatest risk for 266 FECD (**Supplementary Table 2**). The mean (± S.D.) age of FECD cases was significantly 267 younger (69.52 ± 10.04 years) than controls (71.68 ± 6.05 years) (**Fig. 2**). As our algorithm 268 269 implemented different age criteria for FECD cases and controls, we used logistic regression to adjust for this age difference in subsequent multivariable logistic regression models (Table 270 3) but did not formally test for age differences. We incorporated the CCI in the model to 271 determine whether the non-ocular conditions as ascertained by higher scores demonstrated 272 273 association with FECD.

Although women comprise only ~9% of MVP enrollees, we found a much higher risk for females after adjusting for age, and ancestry group (OR=4.60; CI: 4.03 - 5.22; p < 0.001). In fact, female sex was the most significant effect in our analyses. Non-European ancestry (AFR, ASN, HIS) was associated with reduced risk (OR=0.81, 95% CI: 0.71 - 0.91, p < 0.001; OR=0.18, 95% CI: 0.06 - 0.42, p < 0.001; OR=0.53, 95% CI: 0.42 - 0.66, p < 0.001, respectively).

280

FECD is associated with multiple other disease conditions

The CCI predicts long-term mortality for multiple medical conditions and can be used to identify the impact of overall health on diagnostic and prognostic factors.³⁶ After adjusting for other covariates (age, sex and ancestry group), we found that cases with FECD were 1.21 times more likely to have 1-3 comorbid conditions identified via the CCI, compared with a control without FECD (95% CI: 1.06 - 1.39, p = 0.005). A similar analysis of an increasing number of comorbid conditions, 4 or greater, elevated the odds ratio to 1.40 (95% CI: 1.11 -1.75; p = 0.003).

289 We used a PheWAS to better understand the nature of the elevated number of comorbidities noted in our more numerous Veterans of European ancestry. Of the total 290 number of 1,814 diagnostic phecodes, 1,417 met our criteria of including at least 100 cases. 291 Of these, 213 (15.0%) were more prevalent in FECD cases than controls after Bonferroni 292 293 correction (**Supplementary Table 3**). Significant associations were noted in virtually every phecode group (Figure 3; Table 4). The phegroup 'Sense Organs' had the highest number 294 295 and rate of significant phecodes (51 out of 118; 43.22%); the five most significant phecodes were for corneal dystrophy (cornea replaced by transplant, corneal dystrophy, corneal 296 opacity and other disorders, Fuchs dystrophy, corneal edema). Other highly significant 297 phecodes were *inflammation of the eye* (OR=2.25; 95% CI: 2.03 – 2.49; p <2.59 X 10⁻⁵¹), 298 299 dry eyes (OR=1.95; 95% CI: 1.78 – 2.15; p <1.24 X 10⁻⁴⁴), and uveitis, noninfectious or **NOS** (OR=4.43; 95% CI: 3.60 – 5.39; p <8.86 X 10⁻³⁴). The phegroup '**Dermatologic**' also 300 had a high rate of significant phecodes (19 out of 73; 26.0%) and these included corns and 301 callosities (OR=1.56; 95% CI: 1.36 – 1.77; p <1.99 X 10⁻¹⁰), other hypertrophic and 302 atrophic conditions (OR=1.53; 95% CI: 1.36 – 1.72; p <5.78 X 10⁻¹²) and disturbances of 303 skin sensation (OR=1.54; 95% CI: 1.34 – 1.76; p <2.59 X 10-9). The 'Musculoskeletal' 304 phegroup had 16 out of 109 (14.7%) phecodes that were significantly higher in cases than 305 controls, and these included a number related to arthritis (peripheral enthesopathies and 306 allied syndromes (OR=1.45; 95 CI: 1.32 – 1.59; p<8.86 X 10⁻¹⁴), osteoarthritis NOS 307 (OR=1.35; 95% CI: 1.23 – 1.48; p<1.58 X 10⁻¹⁰), and abnormal wear of spinal disks 308 (spondylosis and allied disorders (OR=1.42; 95% CI: 1.27 – 1.58; p<1.68 X 10⁻⁹), 309 spondylosis without myelopathy (OR=1.40; 95% CI: 1.25 – 1.57; p<1.58 X 10⁻⁸). 310

Within the 'Endocrine/Metabolic' phegroup, we noted a number of phecodes related 311 to DM. For example, the odds of having the *insulin pump user* phecode was 2.2 times 312 higher among FECD cases versus controls (95% CI: 1.82 – 2.68; p<2.75 X 10⁻¹³). Phecodes 313 for Type 1 diabetes (OR=2.01; 95% CI: 1.69 – 2.37; p<1.18 X 10⁻¹³) and Type 2 diabetes 314 $(OR=1.25; 95\% CI: 1.15 - 1.37; p < 4.55 X 10^{-7})$ were both more prevalent in FECD cases, 315 along with a number of phecodes related to associations of Type 1 or Type 2 DM and specific 316 systems (neurological, ophthalmic, renal). The phecode **obesity** was also more prevalent in 317 FECD cases (OR=1.34; 95% CI: 1.22 - 1.47; p<1.73 X 10⁻¹⁰) and this may be related to the 318 multiple 'Digestive' (15 out of 146; 10.3%) and 'Respiratory' (12 out of 77; 15.6%) phecodes 319 320 that that were significantly more prevalent in FECD cases than controls.

The only phegroups where FECD cases were not distinguished from controls were (**pregnancy'** (0 out of 1; 0%), '**congenital anomalies**' (1 out of 30; 3.3%) and '**neoplasms**' (3 out of 113; 2.7%). Disorders of pregnancy and congenital anomalies have relative low relevance to the adult Veteran population that we examined.

In our PheWAS for Veterans of AFR ancestry, forty out of 942 (4.25%) phecodes were 325 326 more prevalent in FECD cases than controls. While this analysis had less power due to the smaller sample size, many of the phecodes that were significant reflected our EUR analysis, 327 including Fuchs' dystrophy, corneal dystrophy, corneal opacity and other disorders of 328 cornea, corneal edema, dry eyes, and osteoarthrosis. Both Type 1 and Type 2 DM were 329 more frequent in AFR cases, attaining nominal significance that did not withstand multiple 330 testing correction, but displaying the same direction of effect. In sum, the effects were 331 consistent across groups, but lacked adequate sample sizes in AFR. 332

While more work is needed to fully understand this higher rate of non-ocular phecodes 333 in FECD cases than controls, our analysis of laboratory data were consistent with an 334 important role for DM. Out of the 69 available measures, five were significantly altered in 335 FECD cases of EUR ancestry after Bonferroni correction (Supplementary Table 4). For four 336 of these, the change direction was consistent with DM. FECD cases had elevated levels of 337 hemoglobin A1C (OR=1.11; CI: 1.06 – 1.16; p<2.47 X 10⁻⁶) and serum glucose (OR=1.08; CI: 338 1.03 – 1.13; p=5.54 X 10⁻⁴) while hematocrit (OR=0.90; CI: 0.86 – 0.94; p<1.57 X 10⁻⁶) and 339 hemoglobin (OR=0.90; CI: 0.86 - 0.94; p<2.60 X 10⁻⁶) were decreased. Changes in 340 bicarbonate levels had the strongest association, showing elevation in FECD cases 341 $(OR=1.15; CI: 1.10 - 1.20; p < 7.31 \times 10^{-10})$, but the cause of this pH increase in blood and 342

relationship to FECD is unknown. Hemoglocin A1C and serum glucose were also elevated in
 FECD cases of AFR ancestry, but these changes did not reach statistical significance due to
 the smaller sample size. Effect estimates were consistent with results from the EUR ancestry
 analysis.

In summary, the most important demographic risk factors for FECD are female sex and European ancestry. Further, we note that FECD risk increases with increasing multimorbidity and multiple systemic conditions. The associations with phecodes related to endocrine/metabolic conditions including DM are supported by the significant laboratory values that are associated with FECD.

352

353 Discussion

PheWAS has traditionally been used to identify pleiotropy, where a genetic trait is associated 354 with multiple conditions.²⁰ In this study, we applied the PheWAS approach to the MVP 355 biobank to comprehensively investigate whether FECD may be associated with other 356 conditions. We noted that Veterans with a CCI score of 0 (zero comorbidities) were less 357 358 likely to have a diagnosis of FECD as compared to those with at least one comorbidity. To explore this observation, we examined the association between FECD status and the entire 359 library of phecodes. In comparison to controls, we noted that FECD cases had higher rates of 360 many conditions, including endocrine/metabolic, infectious disease, neurological, and 361 musculoskeletal phegroups and indicating that as a group FECD cases have many more 362 healthcare challenges than controls. Among these, a primary association converged on DM, 363 where we noted that FECD cases had elevated rates of DM-related phecodes and laboratory 364 profiles consistent with DM. 365

What underlies the many associations noted between FECD and other conditions? We 366 favor a model in which these other conditions render the cornea more vulnerable to 367 developing the FECD phenotype. FECD genetic risk factors are incompletely penetrant, so 368 an additional factor is thought to be needed to induce the disease phenotype. A number of 369 such factors that contribute to the FECD phenotype have been identified, including estrogen, 370 oxidative stress, and exposure to UV light.^{4,11} Our results indicate that DM may be a 371 particularly important factor that contributes to FECD etiology. This concept is consistent with 372 a broad literature. For example, DM is known to alter corneal physiology³⁷⁻⁴⁰ leading to 373 complications that increase keratopathy. These include abnormal tear secretion perhaps 374

secondary to reduced goblet cell density, decreased corneal sensitivity, delayed corneal re-375 epithelialization, and altered corneal morphology, function and biomechanics.^{37,41-46} 376 Consistent with these observations, the Cornea Preservation Time Study documented 377 elevated risk for graft failure for eyes that received a cornea transplant from donors with 378 379 DM.⁴⁷ The mechanism underling the association between DM and FECD may involve TCF4. Expansion of a common trinucleotide repeat within the TCF4 locus is strongly linked to 380 FECD,⁴⁸ and *TCF4* had the strongest signal in a large-scale genome wide analysis of 381 FECD.¹⁰ TCF4 (also referred to as E2-2) is involved in the regulation of insulin genes⁴⁹ and is 382 required to maintain the fate of mature plasmacytoid dendritic cells,⁵⁰ a cell type which has 383 been implicated in Type 1 DM.⁵¹ 384

We also noted that the link between FECD and DM was stronger for the earlier onset 385 Type 1 than the Type 2 form, consistent with the relationship between DM and microvascular 386 complications of the retina, kidney, peripheral nervous system and other systems. It will be 387 interesting to determine whether the presence of DM results in a more severe FECD 388 phenotype in patients with comparable risk factors, and whether DM also impacts other 389 390 corneal dystrophies. It will also be interesting to determine, for example, if FECD is reduced in prevalence or severity in patients with well-managed DM and whether the beneficial effects 391 of topical insulin observed in animal models³⁸ will alleviate FECD severity in patients with DM. 392

Diabetes mellitus may also be central to many of the associations between FECD and other phecodes. For example, anemia can be induced by the shorter life span and greater fragility of red blood cells in DM⁵²⁻⁵⁶ In addition, DM has been linked to multiple dermatologic conditions, as well as enthesopathy, osteoarthritis and spinal disk disorders.⁵⁷⁻⁵⁹. In comparison, while DM increases the risk of gout, this may reflect other comorbid conditions and not a direct effect of DM.⁶⁰

We found that FECD had higher rates of other ocular conditions including cataracts 399 and dry eye. Both are more common in DM,³⁷ suggestive of a central role for DM in the 400 etiology of FECD. However, we cannot rule out the possibility that the elevated rate of 401 diagnostic codes for these and potentially other ocular conditions may simply reflect these 402 patients undergoing more intensive ophthalmic care. Further, the association with cataract 403 may reflect that cataract surgery alone can induce a phenotype involving damage to the 404 corneal endothelium and resembling FECD.⁶¹⁻⁶⁵ The association with dry eye may also reflect 405 that FECD symptoms related to corneal pain and/or sensitivity inspire clinicians to add codes 406

related to dry eye to the medical record. Prior studies have reported that patients with FECD
 are more likely to have glaucoma.⁶⁶

We cannot exclude the possibility that pleiotropy underlies some of the FECD associations that we observed. A more complete understanding of the genetic factors that contribute to FECD and conditions associated with FECD will be needed to understand the relative roles played by pleiotropy versus the physiological impacts of diabetes and potentially other disorders on the cornea in FECD etiology.

FECD has been reported to be more common in women than in men.^{4,24,25} While 414 >90% of U.S. Veterans are male, 1.80% of EUR males (=2,057/111,935) and 7.72% 415 416 (=207/2,473) of EUR females were classified as cases, consistent with excess risk to females. Using our case-control algorithm, we observed a 1.78% prevalence of FECD in the 417 MVP (2,663/149,322). This is somewhat lower than prior reports that FECD prevalence is 418 approximately 4%.^{5,64} A lower estimate of FECD prevalence could reflect that MVP enrollees 419 are >90% male³⁵ and that males have a lower occurrence of FECD. A lower estimate of 420 FECD prevalence could also reflect that our FECD algorithm (a) eliminated individuals with a 421 422 single positive code and (b) included many exclusion codes that could potentially co-exist with FECD. Our estimate of FECD prevalence is, however, much higher than an analysis of 423 data from a national managed-care network which found that the prevalence of all corneal 424 dystrophies was less than 0.1%.⁶⁸ This study did not have an age requirement and therefore 425 included data from young patients not yet at risk for FECD. Additional studies of FECD 426 prevalence in large healthcare databases should help to define a precise estimate of FECD 427 428 prevalence.

We further found that FECD frequency was higher in EUR Veterans than in other ancestries, after adjustment for age and sex. This finding agrees with that of Eghrari et al.⁶⁹ who reported a modest reduction in the incidence of FECD in NHB as compared to NHW patients. In comparison, Mahr and colleagues²⁵ did not observe a difference in FECD incidence between NHW and NHB patients based on their analysis of U.S Medicare claims. Any comparative increase in FECD incidence in NHW may reflect previously reported average differences in corneal thickness across populations.⁷⁰

436

437 Limitations and Strengths

As MVP does not provide imaging data, this study was limited to clinical coding, billing, and
prescription data. We addressed this limitation by developing an algorithm to accurately
identify FECD cases and controls within CPRS. Through a local chart review, involving three
VAMC Eye Clinics, we were able to define a final algorithm that had high PPV (probability of
a case identified by the algorithm having FECD) and high NPV (probability of a control
identified by the algorithm not having FECD). Our algorithm thus provides the opportunity to
pursue FECD genetic studies within MVP and additional largescale biobanks.

In contrast to our algorithm for FECD, we did not use a similar approach to validate the many phecodes that were examined in the PheWAS. These phecodes could suffer from coding and diagnostic errors, although we would expect these to be random such errors will reduce power by introducing noise.

This study was limited to the population served by the Veterans Health Administration. While it is unclear that the Veteran and general population are markedly different, it will be valuable to examine these associations in additional patient cohorts, including those including a larger fraction of women enrollees.

The statistical model used to conduct our PheWAS and our analysis of laboratory values adjusted for obvious confounders (age, sex, genetic ancestry). We cannot rule out however, that some hidden residual confounding may remain.

456

457 **Conclusions**

By developing a rules-based algorithm to identify FECD and applying this to a large EHRbased biobank, we provide new insights into the etiology of FECD. In the future it will be important to better understand the relationship between FECD and DM. Insights regarding this relationship may identify opportunities for slowing FECD progression. We anticipate that our case-control algorithm will open the door for further FECD gene discovery.

463

464 **Acknowledgments**

We are grateful to the VINCI and GENISIS support teams, and to the MVP Core Statistical
Analysis team. This publication is solely the responsibility of the authors and does not

- 467 necessarily represent the official views of the NIH. This publication does not represent the
- views of the Department of Veterans Affairs or the United States Government.
- 469

470 **References**

- Vedana G, Villarreal Jr G, Jun AS. Fuchs endothelial corneal dystrophy: current
 perspectives. *Clin Ophthalmol.* 2016;10:321-330.
- Blitzer AL, Colby KA. Update on the surgical management of Fuchs Endothelial
 Corneal Dystrophy. *Ophthalmol Ther.* 2020;9(4):757-765.
- 475 3. Eye Bank Association of America. Eye Banking Statistical Report. Eye Bank
 476 Association of America, Washington, D.C. 2021.
- 477 4. Ong Tone S, Kocaba V, Bohm M, et al. Fuchs endothelial corneal dystrophy: the 478 vicious cycle of Fuchs pathogenesis. *Prog Ret Eye Res.* 2021;80:100863.
- 479 5. Rosenblum P, Stark WJ, Maumenee IH, Hirst LW, Maumenee AE. Hereditary Fuchs'
 480 dystrophy. *Am J Ophthalmol.* 1980;90(4):455-462.
- 481 6. Nanda GG, Alone DP. Review: current understanding of the pathogenesis of Fuchs
 482 endothelial corneal dystrophy. *Molec Vis.* 2019;25:295-310.
- 7. Biswas S, Munier FL, Yardley J, et al. Missense mutations in *COL8A2*, the gene
 encoding the alpha2 chain of type VIII collagen, cause two forms of corneal endothelial
 dystrophy. *Hum Mol Genet.* 2001;10(21):2415-2423.
- B. Gottsch JD, Sundin OH, Liu SH, et al. Inheritance of a novel *COL8A2* mutation defines
 a distinct early-onset subtype of Fuchs corneal dystrophy. *Invest Ophthalmol Vis Sci.* 2005;46(6):1934-1939.
- 489 9. Liu X, Zheng T, Zhao C, Zhang Y, Liu H, Wang L. Genetic mutations and molecular
 490 mechanisms of Fuchs endothelial corneal dystrophy. *Eye Vis.* 2021;8(1):24.
- 491 10. Afshari NA, Igo RP Jr, Morris NJ, et al. Genome-wide association study identifies three
 492 novel loci in Fuchs endothelial corneal dystrophy. *Nat Commun.* 2017;8:14898.
- Liu C, Miyajima T, Melangath G, et al. Ultraviolet A light induces DNA damage and
 estrogen-DNA adducts in Fuchs endothelial corneal dystrophy causing females to be
 more affected. *Proc Natl Acad Sci USA*. 2020;117(1):573-583.
- 496 12. Xu TT, Baratz KH, Fautsch MP, Hodge DO, Mahr MA. Cancer risk in patients with
 497 Fuchs endothelial corneal dystrophy. *Cornea*. 2022;41(9):1088-1093.

- Chang Y-S, Ho C-H, Wang J-J, Tseng S-H, Jan R-L. The sociodemographic and risk
 factors for Fuchs endothelial dystrophy: A nationwide, matched case-control study in
 Taiwan. *J Pers Med.* 2022;12(2):305.
- 50114.Gaziano JM, Concato J, Brophy M, et al. Million Veteran Program: a mega-biobank to502study genetic influences on health and disease. J Clin Epidemiol. 2016;70:214-223.
- Nguyen X-MT, Quaden RM, Song RJ, et al. Baseline characterization and annual
 trends of body mass index for a mega-biobank cohort of US Veterans 2011-2017. J *Health Res Rev Dev Ctries.* 2018;5(2):98-107.
- Pendergrass SA, Crawford DC. Using electronic health records to generate
 phenotypes of research. *Curr Protoc Hum Genet.* 2019;100(1):e80.
- Halladay CW, Hadi T, Anger MD, et al. Genetically guided algorithm development and
 sample size optimization for age-related macular degeneration cases and controls in
 electronic health records from the VA Million Veteran Program. *AMIA Jt Summits Transl Sci Proc. AMIA Jt Summits Transl Sci.* 2019;2019:153-162.
- 18. Nealon CL, Halladay CW, Kinzy TG, et al. Development and evaluation of a rulesbased algorithm for primary open-angle glaucoma in the VA Million Veteran Program. *Ophthalmic Epidemiol.* 2022:29(6):640-648.
- Fihn SD, Francis J, Clancy C, et al. Insights from advanced analytics at the Veterans
 Health Admin. *Health Aff.* 2014;33(7):1203-1211.
- 51720.Denny JC, Bastarache L, Roden DM. Phenome-wide association studies as a tool to518advance prevision medicine. Annu Rev Genomics Hum Genet. 2016:17:353-373.
- Zhang T, Goodman M, Zhu F, et al. Phenome-wide examination of comorbidity burden
 and multiple sclerosis disease severity. *Neurol Neuroimmunol Neuroinflamm*.
 2021;7(6):e864.
- Song RJ, Ho Y-L, Schubert P, et al. Phenome-wide association of 1809 phenotypes
 and COVID-19 disease progression in the Veterans Health Administration Million
 Veteran Program. *PLOS One* 2021;16(5):e0251651.
- 525 23. Yeh P, Colby K. Corneal endothelial dystrophies. In *The Cornea*, Foster CAD,
 526 Dohlman C (Eds). (Lippincott Williams & Wilkins, Philadelphia, 2004).
- 527 24. Wilson SE, Bourne WM. Fuchs dystrophy. *Cornea*. 1988;7(1):2–18.

- 528 25. Mahr MA, Baratz KH, Hodge DO, Erie JC. Racial/ethnic differences in rates of
 529 penetrating or endothelial keratoplasty for Fuchs endothelial corneal dystrophy among
 530 US Medicare beneficiaries, 2014. *JAMA Ophthalmol.* 2016;134(10):1178-1180.
- 531 26. Eghrari AO, Vahedi S, Afshari NA, Riazuddin SA, Gottsch JD. CTG18.1 expansion in
- 532 TCF4 among African Americans with Fuchs corneal dystrophy. *Invest Ophthalmol Vis* 533 *Sci.* 2017;58(14):6046-6049.
- 534 27. Hunter-Zinck H, Shi Y, Li M, et al. Genotyping array design and data quality control in
 535 the Million Veteran Program. *Amer J Hum Genet*. 2020;106(4):535-548.
- 536 28. Fang H, Hui Q, Lynch J, et al. Harmonizing genetic ancestry and self-identified
 537 race/ethnicity in genome-wide association studies. *Amer J Hum Genet*.
 538 2019;105(4):763-772.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
 prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40(5):373-383.
- 54230.Akinyemiju T, Jha M, Moore JX, Pisu M. Disparities in the prevalence of comorbidities543among US adults by state Medicaid expansion status. *Prev Med.* 2016;88:196-202.
- Akinyemiju T, Moore JX. Data on burden of comorbidities in the United States and
 Medicaid expansion status. *Data Brief.* 2016;8:120-122.
- Wei WQ, Bastarache L, Carroll RJ, et al. Evaluating phecodes, clinical classification
 software, and ICD-9-CM codes for phenome-wide association studies in the electronic
 health record. *PLOS One*. 2017;12(7):0175508.
- 33. Wu P Gifford A, Meng X, et al. Mapping ICD-10 and ICD-10-CM codes to phecodes:
 Workflow development and initial evaluation. *JMIR Med Inform.* 2019;7(4):e14325.
- 55134.Carroll RJ, Bastarache L, Denny JC. R PheWAS: data analysis and plotting tools for552phenome-wide association studies in the R environment. *Bioinformatics*.
- 553 **2014;30(16):1375-1376**.
- 35. Harrington KM, Nguyen X-MT, Song RJ, et al. Gender differences in demographic and
 health characteristics of the Million Veteran Program cohort. *Womens Health Issues*2019;29 Suppl 1(Suppl 1):S56-S66.
- S57 36. Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson comobordibity index: A
 critical review of clinimetric properties. *Psychother Psychosom.* 2022;91(1):8-35.

- Skarbez K, Priestley Y, Hoepf M, Koevary SB. Comprehensive review of the effects of
 diabetes on ocular health. *Expert Rev Ophthalmol.* 2010;5(4):557-577.
- 561 38. Ljubimov AJ. Diabetic complications in the cornea. *Vision Res.* 2017;139:138-152.
- 39. Kalteniece A, Ferdousi M, Azmi A, Marshall A, Soran H, Malik RA. Keratocyte density
 Is reduced and related to corneal nerve damage in diabetic neuropathy. *Invest*

564 Ophthalmol Vis Sci. 2018;59(8):3584-3590.

- Shah R, Amador C, Tormanen K, et al. Systemic diseases and the cornea. *Exp Eye Res.* 2021;204:108455.
- Lass JH, Spurney RV, Dutt RM, et al. A morphologic and fluorophotometric analysis of
 the corneal endothelium in type I diabetes mellitus and cystic fibrosis. *Am J Ophthalmol.* 1985;100(6):783-788.
- 42. Weston BC, Bourne WM, Polse KA, Hodge DO. Corneal hydration control in diabetes
 mellitus. *Invest Ophthalmol Vis Sci.* 1995;36(3):586-595.
- 43. Larsson LI, Bourne WM, Pach JM, Brubaker RF. Structure and function of the corneal
 endothelium in diabetes mellitus type I and type II. *Arch Ophthalmol.* 1996;114(1):914.
- 575 44. Ziadi M, Moiroux P, d'Athis P, et al. Assessment of induced corneal hypoxia in diabetic 576 patients. *Cornea.* 2002;21(5):453-457.
- 45. Liaboe CA, Aldrich BT, Carter PC, et al. Assessing the impact of diabetes mellitus on
 donor corneal endothelial cell density. *Cornea.* 2017;36(5):561e566.
- 46. Ramm L, Herber R, Spoerl E, Pillunat LE, Terai N. Factors influencing corneal
 biomechanics in diabetes mellitus. *Cornea.* 2020;39(5):552-557.
- 47. Terry MA, Aldave AJ, Szczotka-Flynn LB, et al. Donor, recipient, and operative factors
 associated with graft success in the Cornea Preservation Time Study. *Ophthalmology*.
 2018;125(11):1700-1709.
- 48. Wieben ED, Aleff RA, Tosakulwong N, Butz ML, Highsmith WE, Edwards AO, Baratz
- 585 KH. A common trinucleotide repeat expansion within the transcription factor 4 (TCF4,
- E2-2) gene predicts Fuchs corneal dystrophy. *PLoS One.* 2012;7(11):e49083.
- 587 49. Vierra CA, Nelson C. The pan basic helix-loop-helix proteins are required for insulin
 588 gene expression. *Molec Endocrinol.* 1995;9(1):64-71.

- 589 50. Ghosh HS, Cisse B, Bunin A, Lewis KL, Reizis B. Continuous expression of the
 590 transcription factor E2-2 maintains the cell fate of mature plasmacytoid dendritic cells.
 591 *Immunity.* 2010;33(6):905-916.
- 592 51. Ye Y, Gaugler B, Mohty M, Malard F. Plasmacytoid dendritic cell biology and its role in 593 immune-related diseases. *Clin Trans Immunol.* 2020;9(5):e1139.
- 52. Craig KJ, Williams JD, Riley SG, Smith H, Owens DR, Worthing D, Cavill I, et al.
 Anemia and diabetes in the absence of nephropathy. *Diabetes Care.* 2005;28(5):11181123.
- 53. El-Achkar TM, Ohmit SE, McCullough PA, Crook ED, Brown WW, Grimm R, Bakris
 GL, et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney
 insufficiency: the kidney early evaluation program. *Kidney Int.* 2005;67(4):1483-1488.
- Ford ES, Cowie CC, Li C, Handelsman Y, Bloomgarden ZT. Iron-deficiency anemia,
 non-iron-deficiency anemia and HbA1c among adults in the US. *J Diabetes*.
 2011;3(1):67-73.
- 55. Lippi G, Mercadanti M, Aloe R, Targher G. Erythrocyte mechanical fragility is
 increased in patients with type 2 diabetes. *Eur J Intern Med.* 2012;23(2):150-153.
- Knychala MA, da Silva Garrote-Filho M, da Silva BB, de Oliveira SN, Luz SY,
 Rodrigues MOM, Penha-Silva N. Red cell distribution width and erythrocyte osmotic
 stability in type 2 diabetes mellitus. *J Cell Mol Med.* 2021;25(5):2505-2516.
- 57. Piva SR, Susko AM, Khoja SS, Josbeno DA, Fitzgerals GK, Toledo FGS. Links
 between osteoarthritis and diabetes: Implications for management from a physical
 activity perspective. *Clin Geriatr Med.* 2015;31(1):67-87.
- 58. Ursini F, Arturi F, Nicolosi K, et al. Plantar fascia enthesopathy is highly prevalent in
 diabetic patients without peripheral neuropathy and correlates with retinopathy and
 impaired kidney function. *PLoS One.* 2017;12(3):e0174529.
- 614 59. Park C-H, Min K-B, Min J-Y, Kim DH, Seo KM, Kim D-K. Strong association of type 2
 615 diabetes with degenerative lumbar spine disorders. *Scientific Rep.* 2021;11(21):16472.
- 616 60. Wijnands JMA, van Durme DM, Ghislaine P, Driessen JHM, Boonen A, Klop C,
- Leufkens B, Cooper C, Stehouwer CDA, de Vries F. Individuals with Type 2 diabetes mellitus are at an increased risk of gout but this is not due to diabetes. A populationbased cohort study. *Medicine*. 2015;94(32):e1358.
 - 20

- 61. Walkow T, Anders N, Klebe S. Endothelial cell loss after phacoemulsification: relation
 to preoperative and intraoperative parameters. *J Cataract Refract Surg.*2000;26(5):727–732.
- 62. Seitzman GD, Gottsch JD, Stark WJ. Cataract surgery in patients with Fuchs' corneal
 624 dystrophy: expanding recommendations for cataract surgery without simultaneous
 625 keratoplasty. *Ophthalmology*. 2005;112(3):441-446.
- 63. Güell JL, El Husseiny MA, Manero F, Gris O, Elies D. Historical review and update of
 surgical treatment for corneal endothelial diseases. *Ophthalmol Ther.* 2014;3(1-2):115.
- 64. van Cleynenbreugel H, Remeijer L, Hillenaar T. Cataract surgery in patients with
 Fuchs' endothelial corneal dystrophy: when to consider a triple procedure.
 Ophthalmology. 2014;121(2):445-453.
- 65. Yong WWD, Chai HC, Shen L, Manotosh R, Anna Tan WT. Comparing outcomes of
 phacoemulsification with femtosecond laser-assisted cataract surgery in patients with
 Fuchs endothelial dystrophy. *Am J Ophthalmol.* 2018;196:173-180.
- 635 66. Nagarsheth M, Singh A, Schmotzer B, et al. Relationship between Fuchs endothelial
 636 corneal dystrophy severity and glaucoma and/or ocular hypertension. *Arch*637 *Ophthalmol.* 2012;130(11):1384-1388.
- 67. Elhalis H, Azizi B, Jurkunas UV. Fuchs endothelial corneal dystrophy. *The Ocular Surface* 2010 8(4):173-184.
- 68. Musch DC, Niziol LM, Stein JD, Kamyar RM, Sugar A. Prevalence of corneal
 dystrophies in the United States: estimates from claims data. *Invest Ophthalmol Vis Sci.* 2011;52(9):6959-6963.
- 643 69. Eghrari AO, Vahedi S, Afshari NA, Riazuddin SA, Gottsch JD. CTG18.1 Expansion in
 644 TCF4 among African Americans with Fuchs' Corneal Dystrophy. *Invest Ophthalmol Vis*645 *Sci.* 2017;58(14):6046-6049.
- McGlumphy EJ, Margo JA, Haidara M, Brown CH, Hoover CK, Munir WM. Predictive
 value of corneal donor demographics on endothelial cell density. *Cornea*.
 2018;37(9):1159-1162.

650 Figure Legends

- **Figure 1:** Overview of the algorithm refinement process and application to MVP. FECD
- case-control algorithms were evaluated and revised at the Cleveland VAMC Eye Clinic. Upon
- reaching >85% PPV and >95% NPV, algorithm performance was confirmed at Buffalo and
- 654 Providence VAMC Eye Clinics, and then applied to the MVP.
- 655
- Figure 2: Age distribution of FECD cases (N=2,663) (a) and controls (N=138,944) (b). (c)
 Box-plot representation.

658

- **Figure 3:** Phenome-wide association scan of EHR-derived phenotypes (main panel) and
- normalized laboratory values (inset) with FECD. Upwards-pointing arrows indicate positive
- association (OR > 1) and downwards-pointing arrows indicate negative association (OR < 1).
- Red line indicates Bonferroni-corrected significance threshold. Phenotypes highly similar to
- FECD are not plotted. Labs shown are those significant after multiple hypothesis testingcorrection.

Table 1: Summary of Cases and Controls reviewed in final FECD algorithm.

		Algorithm Identified			
		FECD cases (female)	Controls (female)	PPV	NPV
Non-Hispanic Black	Cleveland	25 (4)	25 (0)	96%	96%
	Providence	1 (0)	25 (0)	100%	100%
	Buffalo	17 (3)	25 (1)	88%	100%
	Combined	43 (7)	75 (1)	93%	98%
Non-Hispanic White	Cleveland	25 (2)	25 (0)	80%	92%
	Providence	25 (0)	24 (0)	76%	100%
	Buffalo	25 (2)	25 (0)	72%	96%
	Combined	75 (4)	74 (0)	76%	96%
Total		118 (11)	149 (1)	82%	97%

667 FECD: Fuchs endothelial corneal dystrophy

668 PPV: positive predictive value

669 NPV: negative predictive value

670

Table 2: Genotyped MVP participants who meet the criteria for case with FECD or control.

Genetic	Cases	Controls	% FECD
ancestry	all / male / female	all / male / female	all / male / female
EUR	2,264 / 2,057 / 207	114,408 / 111,935 / 2,473	1.94 / 1.80 / 7.72
AFR	315 / 225 / 90	16,367 / 15,907 / 460	1.89 / 1.39 / 16.36
HIS	80 / 75 / 5	7,105 / 6,962 / 143	1.11 / 1.07 / 3.38
ASN	4 / 4 / 0	1,064 / 1,035 / 29	0.37 / 0.38 / not done
Total	2,663 / 2,361 / 302	138,944 / 135,839 / 3,105	1.88 / 1.71 / 8.86

- 673 MVP: Million Veteran Program
- 674 FECD: Fuchs endothelial corneal dystrophy
- 675 EUR: European ancestry
- 676 AFR: African ancestry
- 677 ASN: Asian ancestry
- 678 HIS: admixed American ancestry
- 679

- **Table 3:** Multivariable logistic regression examining various factors influencing risk to FECD
- 682 (N = 141,607).

Variable	OR	95% CI	P value
Age	0.92	0.92, 0.93	< 0.001
Sex	4.60	4.03, 5.22	< 0.001
Ancestry – AFR vs EUR	0.81	0.71, 0.91	< 0.001
Ancestry – HIS vs EUR	0.53	0.42, 0.66	< 0.001
Ancestry – ASN vs EUR	0.18	0.06, 0.42	< 0.001
CCI Cat 1-3	1.21	1.06, 1.40	0.005
CCI Cat 4+	1.40	1.11, 1.75	0.003

- 683 FECD: Fuchs endothelial corneal dystrophy
- 684 AFR: admixed African ancestry
- 685 EUR: European ancestry
- 686 HIS: admixed American ancestry (Hispanic/Latino)
- 687 ASN: Asian ancestry
- 688 CCI: Charlson Comorbidity Index
- 689 OR: odds ratio
- 690 CI: confidence interval

Table 4: Summary of PheWAS organized by phecode groups. For each phecode group, the

total number of phecodes that included at least 100 cases and those that achieved statistical

694 significance after Bonferroni correction are noted.

	Total	Significant	%
Phecode group	phecodes	phecodes	significant
circulatory system	17	156	10.90
congenital anomalies	1	30	3.33
dermatologic	19	73	26.03
digestive	15	146	10.27
endocrine/metabolic	21	122	17.21
genitourinary	11	106	10.38
hematopoietic	3	47	6.38
infectious diseases	8	50	16.00
injuries & poisonings	8	91	8.79
mental disorders	8	67	11.94
musculoskeletal	16	109	14.68
neoplasms	2	113	1.77
neurological	11	73	15.07
pregnancy	0	1	0.00
complications			
respiratory	12	77	15.58
sense organs	51	118	43.22
symptoms	10	38	26.32
TOTAL	213	305	15.03



Figure 1: Overview of the algorithm refinement process and application to MVP. FECD case-control algorithms were evaluated and revised at the Cleveland VAMC. Upon reaching >85% PPV and >95% NPV, algorithm performance was confirmed at Buffalo and Providence VAMCs, and then applied to the MVP.



Figure 2: Age distribution of FECD cases (N=2,663) (a) and controls (N=138,944) (b). (c) Box-plot representation.

Figure 3



Figure 3. Phenome-wide association scan of EHR-derived phenotypes (main panel) and normalized laboratory values (inset) with FECD. Upwards-pointing arrows indicate positive association (OR > 1) and downwards-pointing arrows indicate negative association (OR < 1). Red line indicates Bonferroni-corrected significance threshold. Phenotypes highly similar to FECD are not plotted. Labs shown are those significant after multiple hypothesis testing correction.